Susceptibility of Multidrug-Resistant Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa from Germany to Ceftolozane–Tazobactam, Ceftazidime–Avibactam, and Imipenem–Relebactam
Authors:
- Michael KreskenMKMichael Kresken
- Karsten BeckerKBKarsten Becker
- Sören BeckerSBSören Becker
- Thomas DemantTDThomas Demant
- Ulrich EignerUEUlrich Eigner
- Reinhard HoffmannRHReinhard Hoffmann
- 6 April 2023
- journal article
- research article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 29 (4) , 138-144
Abstract
This cross-sectional in-vitro resistance surveillance study involving 10 medical laboratories was conducted in 2018. Each study site was asked to collect 30 consecutive nonduplicate isolates per species from hospitalized patients with documented infections. Minimum inhibitory concentrations were determined at a central laboratory. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for interpretation. A total of 860 isolates were collected, including 298 Escherichia coli , 268 Klebsiella pneumoniae , and 294 Pseudomonas aeruginosa . Fifty (16.8%) E. coli and 63 (23.5%) K. pneumoniae isolates were found to be resistant to third-generation cephalosporins. Resistance to carbapenems (imipenem and/or meropenem) was identified in 5 (1.9%) K. pneumoniae and 64 (21.8%) P. aeruginosa , but not in E. coli . Thirty-three (11.2%) P. aeruginosa isolates were resistant to both carbapenems and 30 (10.2%) P. aeruginosa showed resistance to ≥3 antimicrobials/antimicrobial groups (among piperacillin–tazobactam, ceftazidime, tobramycin, carbapenems, and fluoroquinolones). The susceptibility rates of these multidrug-resistant (MDR) phenotypes to ceftolozane–tazobactam, ceftazidime–avibactam, and imipenem–relebactam were 70–100%, with the exception of carbapenem-resistant K. pneumoniae . Only two K. pneumoniae and four P. aeruginosa isolates were resistant to all three beta-lactam/beta-lactamase-inhibitor combinations. However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany.Keywords
This publication has 9 references indexed in Scilit:
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- New β-Lactam–β-Lactamase Inhibitor CombinationsClinical Microbiology Reviews, 2020
- Phenotypic Detection and Differentiation of Carbapenemase Classes Including OXA-48-Like Enzymes in Enterobacterales and Pseudomonas aeruginosa by a Highly Specialized Micronaut-S Microdilution AssayJournal of Clinical Microbiology, 2020
- Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in GermanyInternational Journal of Antimicrobial Agents, 2020
- Treatment Options for Carbapenem-resistant Gram-negative Bacterial InfectionsClinical Infectious Diseases, 2019
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosisThe Lancet Infectious Diseases, 2018
- In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in GermanyInternational Journal of Antimicrobial Agents, 2018
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Interval Estimation for a Binomial ProportionStatistical Science, 2001